Walmart Reaches $50 Million Settlement Over Opioid Prescription Allegations
Key Takeaways
- Walmart has agreed to pay $50 million to resolve federal allegations that its pharmacies illegally filled thousands of invalid opioid and other controlled substance prescriptions.
- The settlement requires Walmart to strengthen controlled substance compliance through enhanced dispensing monitoring, prescriber evaluations, and a reporting hotline.
- The case underscores pharmacists’ responsibility to identify and resolve potential red flags before dispensing controlled substances and appropriately escalate concerns.
Walmart Inc has agreed to pay $50 million to resolve federal allegations that its pharmacies illegally filled thousands of invalid prescriptions for opioids and other controlled substances in violation of the Controlled Substances Act (CSA).1
The settlement, announced by the US Department of Justice (DOJ) and Drug Enforcement Administration (DEA), also requires Walmart to implement additional measures intended to identify potentially unlawful prescribing and dispensing of controlled substances.1
The claims resolved by the settlement are allegations only, and there has been no determination of liability.1
DOJ Alleged Walmart Pharmacies Filled Invalid Prescriptions
The federal government filed its original complaint against Walmart on December 22, 2020, and amended it in 2022 in the US District Court for the District of Delaware. The complaint alleged that, beginning June 26, 2013, Walmart filled invalid prescriptions through the knowing actions of members of its compliance team and pharmacists.1
Under the CSA, controlled substances may be dispensed only pursuant to a valid prescription issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice. Pharmacists also are required to follow the usual course of professional pharmacy practice, including identifying and resolving potential “red flags” before dispensing a controlled substance.2
According to the government, Walmart’s compliance team knew that certain prescribers were operating as “pill mills” after pharmacists reported concerns through thousands of “refusal-to-fill” forms. However, the government alleged that the company continued filling invalid prescriptions from some of those prescribers.1,2
The complaint further alleged that Walmart pharmacists filled prescriptions containing indicators of potential invalidity, including dangerous combinations of opioids, combinations of opioids and nonopioids, repeated fills of high doses of frequently abused opioids, and repeated requests for early fills of controlled substances.1,2
Federal prosecutors also alleged that Walmart, which previously served as a wholesale distributor of controlled substances to its own pharmacies, failed to adequately detect and report suspicious controlled substance orders to the DEA.1
Settlement Establishes New Controlled Substance Compliance Requirements
Beyond the $50 million payment, Walmart entered into a memorandum of agreement with the DEA addressing the company’s future controlled substance dispensing obligations.1
Under the agreement, Walmart must establish a hotline through which employees and patients can report suspected illegal dispensing of controlled substances. The company must also proactively monitor pharmacy dispensing patterns to identify and address potentially illegal activity and establish a process for evaluating prescribers suspected of unlawful prescribing.1
“This $50 million settlement makes clear that pharmacies have a responsibility to identify and prevent the unlawful dispensing of controlled substances,” DEA Assistant Administrator Cheri Oz said in the DOJ announcement.1
“We are pleased to resolve this matter and will continue supporting the exceptional work our pharmacists do every day to provide outstanding patient care,” a Walmart spokesperson said.3
Why Does It Matter for Pharmacists?
The case highlights pharmacists’ responsibilities when dispensing controlled substances and the importance of identifying and resolving potential warning signs before a prescription is filled.1,2
The original federal complaint characterized pharmacies as the final step in the controlled substance supply chain before medications reach patients. It alleged that pharmacists must determine whether controlled substance prescriptions were issued for a legitimate medical purpose in the usual course of professional practice and address potential red flags indicating that a prescription may be invalid.2
The settlement also demonstrates the role of pharmacy-level reporting in broader corporate compliance. The government’s allegations relied in part on concerns Walmart pharmacists had reported internally about prescribers and controlled substance prescriptions.1,2
Bottom Line
Walmart’s $50 million settlement resolves federal allegations that its pharmacies improperly filled thousands of invalid opioid and other controlled substance prescriptions. In addition to the monetary payment, the agreement requires enhanced reporting, monitoring, and prescriber-evaluation measures intended to strengthen controlled substance compliance across Walmart pharmacies.
For pharmacists, the case reinforces the importance of recognizing and resolving dispensing red flags, documenting concerns, and escalating suspected unlawful prescribing through established compliance channels.
References
- US Department of Justice. Walmart agrees to pay $50 million for illegally filling unlawful opioid prescriptions. Published August 28, 2026. Updated September 1, 2026. Accessed September 2, 2026. https://www.justice.gov/opa/pr/walmart-agrees-pay-50-million-illegally-filling-unlawful-opioid-prescriptions
- United States of America v Walmart Inc. No. 1:99-mc-09999 (D. Del. filed Dec. 22, 2020). US Dept of Justice archives. Accessed September 2, 2026. https://www.justice.gov/archives/opa/press-release/file/1347906/dl
- Cunningham M. Walmart settles Justice Department opioid lawsuit. Published August 28, 2026. CBS News. Accessed September 2, 2026. https://www.cbsnews.com/news/walmart-settles-justice-department-opioid-lawsuit/
